Trial Profile
Biomarker study of "A Phase III Trial of Docetaxel plus S-1 versus S-1 Alone in the Treatment of Curatively Resected Stage III Gastric Cancer (JACCRO GC-07(START-2))"
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Jan 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Gastric cancer
- Focus Biomarker; Pharmacodynamics
- 18 Jan 2021 According to University Hospital Medical Information Network - Japan, Date of closure to data entry is 30 Sep 2022.
- 14 Mar 2018 New trial record